Quanta Therapeutics is a private biopharmaceutical company focused on the most prevalent and elusive target in oncology-RAS. Our vision is to develop novel small molecule cancer medicines by selectively targeting protein-protein interactions that are key to oncogenic RAS activity. Driving Quanta's success is our unique high-throughput platform that applies Second Harmonic Generation (SHG) optical technology to identify allosteric modulators of membrane-bound protein complexes. The Quanta team has extensive drug development expertise and substantial research experience in the RAS space. By applying innovative medicinal chemistry and its unique protein conformation detection technology, Quanta aims to advance differentiated, next-generation RAS programs that address the resistance paradigms of targeted therapy in oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/22/23 | $50,700,000 | Series D |
AbbVie Ventures Avidity Partners  BVF Partners GC&H Investments Longitude Capital Sofinnova Ventures Surveyor Capital Vida Ventures WS Investments | undisclosed |
